Announcements Trials

Browse Landscape

Phase

Status

Completed 147 Terminated 34 Active not recruiting 5 Withdrawn 4 Unknown 4 Suspended 1 Recruiting 1

Sponsor Class

OTHER 8 NIH 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 241 Carboplatin 170 Injections 139 Paclitaxel 122 Gemcitabine 118 Bevacizumab 117 Cisplatin 108 Pemetrexed 80 Docetaxel 80 Cyclophosphamide 74 Capecitabine 69 Fluorouracil 67 Oxaliplatin 65 Fulvestrant 60 Nivolumab 55 Cetuximab 53 fludarabine 52 Leucovorin 51 130-nm albumin-bound paclitaxel 50 Dexamethasone 46 Rituximab 41 atezolizumab 38 venetoclax 35 toripalimab 35 Drug Therapy 35 enzalutamide 32 Prednisone 32 Letrozole 32 Irinotecan 32 durvalumab 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × INDUSTRY × Erlotinib Hydrochloride × Clear all

NCT05442060 2025-08-03

EGFR

OBI Pharma, Inc

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡